



Life Sciences *Meets Aesthetics*



Anthony Aho
Bioengineer & CEO PB&B Inc.

Aesthetic Innovation Summit 2019

PB&B | Disrupting Aesthetics

85% of Plastic Surgeons:
Fat is the future

Beauty through Science International
Aesthetic Medicine Congress


Stockholm, Sweden 2012

Facial Aging


FACT / Fat tissues lose volume with aging, causing sagging and wrinkles.

TREATMENT


Fillers



Age: **35**



Age: **45**



Age: **55**

Fillers
replace
lost fat
volume




re-volumizes fat



PB&B product use

Easy-use, Fast, and Efficient



**1. PB&B
Product**

**2. Add sterile
water**

**3. Shake
(20 sec)**

**4. Load
syringe**


**5. Inject to
enhance volume**

Molecular-Based Solution & Precision

GOAL / To increase fat cell volume with lipids.

Adipocyte

Adipocytes (fat cells) store fatty acids in the form of triglycerides



fatty acid

lipid
reservoir

nucleus


triglyceride

De novo absorbed lipids are stored as triglycerides for **~20 months**¹

¹Arner *et al.* Dynamics of human adipose lipid turnover in health & metabolic disease, Nature (Oct 2011)

Patented Technology


Controlled lipid release system for fat volume enhancement.



Biodegradable Microsphere


- induces collagen production
- 2 months bioresorption

**Fat volume enhanced
~20 months**



PB&B: Best of Fillers & Fat Transfer

PB&B: **Gold-standard** results of fat transfer + ease of use & safety of fillers.




PB&B products

Platform technology to remodel face & body:

1. Anti-aging Facial **Filler**

- Natural results
- Long-term
- Most cost-effective




2. **Body remodelling** injection

- Natural results
- Non-surgical
- Highest safety
- Fast & cost-effective



Market



- \$6 Billion**
Addressable Market:
- 50% of Facial Injectables
 - Breast Implants
 - Buttock Augmentation (not on chart)

Source: Decision Research Group

Moving forward

FACE

- Clinical pilot (2019-20)
- Pivotal clinical trial (2020-21)
- FDA approval + CE mark (2020-21)

BODY

- Pre-clinical testing (2019-20)
- Clinical pilot (2020-21)






Anthony Aho CEO & co-founder PB&B Inc.

L / Palo Alto, USA | Lausanne, Switzerland

E / anthony.aho@pbbtech.com

W / www.pbbtech.com

SPONSORS



Federal Department of Economic Affairs,
Education and Research EAER

Commission for Technology and Innovation CTI
Innovation Promotion Agency



This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 809263